Matching articles for "Issue 1336"

Dutasteride (Avodart) for Prevention of Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart – GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic...
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart – GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic hyperplasia, reduced the risk of prostate cancer over a 4-year period.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):29 | Show Full IntroductionHide Full Introduction

Edluar - A New Sublingual Formulation of Zolpidem

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of...
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of insomnia.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):29-30 | Show Full IntroductionHide Full Introduction

Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
Fentanyl buccal soluble film (Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid...
Fentanyl buccal soluble film (Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid therapy. It is designated as a Schedule II controlled substance Two other oral transmucosal formulations of fentanyl are already available for this indication.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):30-1 | Show Full IntroductionHide Full Introduction

L-Methylfolate (Deplin) for Depression and Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by...
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by prescription.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):31-2 | Show Full IntroductionHide Full Introduction

Correction: Ferumoxytol (Feraheme)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):32 | Show Full IntroductionHide Full Introduction